ABT-530
Showing 1 - 25 of 393
Chronic Hepatitis C Virus (HCV) Infection Trial (ABT-493/ABT-530, Placebo for ABT-493/ABT-530)
Completed
- Chronic Hepatitis C Virus (HCV) Infection
- ABT-493/ABT-530
- Placebo for ABT-493/ABT-530
- (no location specified)
Jul 14, 2021
Chronic Hepatitis C, Hepatitis C Virus, HCV Trial (ABT-493/ABT-530)
Completed
- Chronic Hepatitis C
- +2 more
- (no location specified)
Jul 9, 2021
Chronic Hepatitis C, Hepatitis C Virus Trial (ABT-493, ABT-530, ribavirin (RBV))
Chronic Hepatitis C Virus, Hepatitis C Virus Trial (ABT-493/ABT-530, sofosbuvir (SOF), ribavirin (RBV))
Completed
- Chronic Hepatitis C Virus
- Hepatitis C Virus
- ABT-493/ABT-530
- +2 more
- (no location specified)
Jul 14, 2021
Chronic Hepatitis C, Hepatitis C Virus, Genotype 3 Hepatitis C Virus Trial (ABT-493/ABT-530, Sofosbuvir, Daclatasvir)
Chronic Hepatitis C Virus, Hepatitis C Virus Trial (ABT-493/ABT-530, OBV/PTV/r)
Completed
- Chronic Hepatitis C Virus
- Hepatitis C Virus
- (no location specified)
Jul 14, 2021
Hepatitis C Virus Infection, Chronic Hepatitis C, Compensated Cirrhosis Trial (ABT-493/ABT-530)
Completed
- Hepatitis C Virus Infection
- +2 more
- (no location specified)
Jul 9, 2021
Hepatitis C Virus Infection, Human Immunodeficiency Virus Infection, Chronic Hepatitis C Trial (ABT-493 coformulated with
Completed
- Hepatitis C Virus Infection
- +3 more
- ABT-493 coformulated with ABT-530
- (no location specified)
Jul 9, 2021
Chronic Hepatitis C, Hepatitis C Virus, Compensated Cirrhosis Trial (ABT-493, ABT-530, ABT-450/r/ABT-267, ABT-333)
Chronic Hepatitis C, HCV, Hepatitis C Virus Trial (glecaprevir/pibrentasvir)
Completed
- Chronic Hepatitis C
- +2 more
- (no location specified)
Jul 9, 2021
Chronic Hepatitis C, Hepatitis C Virus, HCV Trial (ABT-493, ABT-530)
Hepatitis C Virus (HCV) Trial in Worldwide (Glecaprevir/pibrentasvir adult formulation, Glecaprevir/pibrentasvir pediatric
Completed
- Hepatitis C Virus (HCV)
- Glecaprevir/pibrentasvir adult formulation
- Glecaprevir/pibrentasvir pediatric formulation
-
San Francisco, California
- +37 more
Sep 19, 2022
Hepatitis C Virus Infection Trial in Ljubljana (glecaprevir, pibrentasvir)
Approved for marketing
- Hepatitis C Virus Infection
-
Ljubljana, SloveniaUniv Medical Ctr Ljubljana /ID# 161419
Jan 14, 2020
Hepatitis C Virus (HCV) Trial in Worldwide (Glecaprevir/Pibrentasvir)
Completed
- Hepatitis C Virus (HCV)
-
San Diego, California
- +24 more
Jul 14, 2021
Hepatitis C Virus (HCV) Trial in China, Korea, Republic of (Glecaprevir/Pibrentasvir)
Completed
- Hepatitis C Virus (HCV)
-
Beijing, Beijing, China
- +33 more
Nov 4, 2019
Hepatitis C Virus (HCV) Trial in Worldwide (Glecaprevir/Pibrentasvir (GLE/PIB))
Recruiting
- Hepatitis C Virus (HCV)
- Glecaprevir/Pibrentasvir (GLE/PIB)
-
Chandler, Arizona
- +62 more
Aug 8, 2022
Hepatitis C Virus (HCV) Trial in China, Korea, Republic of, Singapore (Placebo, Glecaprevir/Pibrentasvir)
Completed
- Hepatitis C Virus (HCV)
- Placebo
- Glecaprevir/Pibrentasvir
-
Beijing, Beijing, China
- +47 more
Dec 5, 2019
Hepatitis C Virus (HCV) Trial in Brazil (Glecaprevir/Pibrentasvir)
Completed
- Hepatitis C Virus (HCV)
-
Vitoria, Espirito Santo, Brazil
- +13 more
Mar 4, 2020
Rheumatoid Arthritis (RA) Trial in Worldwide (Elsubrutinib, Upadacitinib, Placebo for elsubrutinib)
Terminated
- Rheumatoid Arthritis (RA)
- Elsubrutinib
- +3 more
-
Woluwe-Saint-Lambert, Bruxelles-Capitale, Belgium
- +29 more
Aug 18, 2021
Ulcerative Colitis (UC) Trial in Worldwide (Upadacitinib (ABT-494), Placebo)
Active, not recruiting
- Ulcerative Colitis (UC)
- Upadacitinib (ABT-494)
- Placebo
-
Mobile, Alabama
- +490 more
Jan 18, 2022
Ulcerative Colitis (UC) Trial in Worldwide (Placebo, Upadacitinib)
Chronic Hepatitis C Virus (HCV) Infection Genotype 1 Trial in United States (ABT-450/r/ABT-267, ABT-333, Ribavirin (RBV))
Completed
- Chronic Hepatitis C Virus (HCV) Infection Genotype 1
- ABT-450/r/ABT-267
- +2 more
-
Phoenix, Arizona
- +47 more
Jun 27, 2022
Idiopathic Pulmonary Fibrosis Trial in Birmingham (Venetoclax)
Not yet recruiting
- Idiopathic Pulmonary Fibrosis
-
Birmingham, AlabamaA. Brent Carter
Aug 3, 2023